Context Therapeutics Shares Are Trading Higher After the Company Announced FDA Clearance of Its IND Application for a Phase 1 Clinical Trial of CTIM-76
Context Therapeutics宣佈美國食品藥品管理局批准其 CTIM-76 1期臨床試驗的IND申請後,該公司股價走高
Context Therapeutics Shares Are Trading Higher After the Company Announced FDA Clearance of Its IND Application for a Phase 1 Clinical Trial of CTIM-76
Context Therapeutics宣佈美國食品藥品管理局批准其 CTIM-76 1期臨床試驗的IND申請後,該公司股價走高
使用瀏覽器的分享功能,分享給你的好友吧